Alnylam Pharmaceuticals Reports Q3 Net Income of USD 2,167.335 Million
Story updates
12:04:36 PM UTC
SquawkNews
ALNYLAM PHARMACEUTICALS Q3 ADJUSTED NET INCOME USD 2,241.91 MILLION
Related stories
PHINIA Reports Q3 Sales of $912 Million, Raises 2026 Outlook
PHINIA reported third-quarter 2026 net sales of $912 million, up 0.4% year over year. It now projects full-year 2026 sales of $3.63 billion to $3.68 billion.
M impact | EARNINGS | Oct 29, 2026, 01:34 PM UTC
Gulf International Services Reports 9-Month Revenue of 3.5 Billion Riyals
L impact | EARNINGS | Oct 29, 2026, 01:34 PM UTC
KBR Reaffirms 2026 Adjusted EPS Outlook of $3.87-$4.22
KBR reaffirmed its fiscal 2026 adjusted EPS outlook at $3.87-$4.22.
L impact | EARNINGS | Oct 29, 2026, 01:33 PM UTC
Allied Gold Targets 25,000–35,000 Ounces at Kurmuk in Nov-Dec 2026
Wet commissioning is underway at the Ethiopia mine. Allied Gold projects first-quarter 2027 production of 55,000–65,000 ounces, maintains 2027 guidance of 240,000–270,000 ounces an
M impact | EARNINGS | Oct 29, 2026, 01:33 PM UTC
Federal Signal Reports Q3 Sales Growth, Raises EPS Outlook
Federal Signal reported third-quarter 2026 net sales of $656 million, up 18% year over year, and diluted EPS of $1.29. It raised full-year adjusted EPS guidance to $5.20–$5.32 from
M impact | EARNINGS | Oct 29, 2026, 01:33 PM UTC
ATI Reports Q3 2026 Sales of $1.42 Billion, Raises EBITDA Forecast
ATI reported net income of $190 million, or $1.37 per share on a GAAP basis, and adjusted EBITDA of $327.9 million, up 46% year over year. It raised its full-year 2026 adjusted EBI
M impact | EARNINGS | Oct 29, 2026, 01:33 PM UTC